{
    "sources": [
        {
            "title": "Spirooxadiazoline-oxindoles derived from imatinib show antimyeloproliferative potential in K562 cells",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38627294"
        },
        {
            "title": "MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38627702"
        },
        {
            "title": "Venetoclax was associated with total monthly cost savings versus BTKis",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38626793"
        },
        {
            "title": "Prognostic Implications of Circulating Plasma Cell Percentage in Multiple Myeloma and Primary Plasma Cell Leukemia Defined by New Criteria",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38626745"
        }
    ],
    "summary": "The collected data on leukemia highlights several key insights, including the development of novel therapeutic agents, the importance of specific biomarkers in diagnosis and prognosis, and the economic implications of treatment choices. Notably, research shows promising results with Spirooxadiazoline-oxindoles derived from imatinib for antimyeloproliferative effects in K562 cells, suggesting potential advancements in treatment strategies. Furthermore, MNDA expression analysis provides a nuanced understanding of its diagnostic value across different B-cell non-Hodgkin lymphomas. Economic studies indicate that Venetoclax may offer cost-effective treatment options compared to BTK inhibitors. Additionally, the revised criteria for diagnosing primary plasma cell leukemia (pPCL) with a lower threshold of circulating plasma cells emphasize the evolving understanding and management of the disease."
}